Trials / Terminated
TerminatedNCT04027348
Palliative Management of Inoperable Malignant Bowel Obstruction
Palliative Management of Inoperable Malignant Bowel Obstruction: A Prospective, Open Label, Phase-2 Study at an NCI Comprehensive Cancer Center
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Roswell Park Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To identify the role of palliative medical management of inoperable malignant bowel obstruction (MBO) with Octreotide, Dexamethasone and Metoclopramide given together as triple therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexamethasone | Given IV |
| DRUG | Metoclopramide | Given IV |
| DRUG | Octreotide | Given IV |
Timeline
- Start date
- 2019-06-26
- Primary completion
- 2021-09-03
- Completion
- 2021-09-03
- First posted
- 2019-07-22
- Last updated
- 2022-11-29
- Results posted
- 2022-11-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04027348. Inclusion in this directory is not an endorsement.